| 1 | Oral treprostinil (UT-15C) Sustained Release Tablets | [1] Treprostinil Treprostinil | [1] D06213
D06213
| [1] PTGIR PTGIR 💬 | [3] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | [1] 86 86 |
| 2 | UT-15C | - | - | - | - | [1] 86 86 |
| 3 | UT-15C (treprostinil diethanolamine) | [1] Treprostinil Treprostinil | [1] D06213
D06213
| [1] PTGIR PTGIR 💬 | [3] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | [1] 86 86 |
| 4 | UT-15C 0.25 mg | - | - | - | - | [1] 86 86 |
| 5 | UT-15C 1 mg | - | - | - | - | [1] 86 86 |
| 6 | UT-15C 5 mg | - | - | - | - | [1] 86 86 |
| 7 | UT-15C LP | - | - | - | - | [1] 86 86 |
| 8 | UT-15C SR | - | - | - | - | [2] 51 51, 86 |
| 9 | UT-15C SR (treprostinil diethanolamine) | [1] Treprostinil Treprostinil | [1] D06213
D06213
| [1] PTGIR PTGIR 💬 | [3] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | [1] 86 86 |
| 10 | UT-15C-SR | - | - | - | - | [2] 51 51, 86 |